Alemtuzumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Alemtuzumab and local guidelines before prescribing.

Anti-CD52 monoclonal antibody

Mechanism

CD52 monoclonal antibody depleting lymphocytes.

Uses

Relapsing multiple sclerosis, CLL, transplant conditioning.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Infusion reactions, autoimmune thyroid disease, ITP, anti-GBM disease, infections.

Interactions

Live vaccines contraindicated.

Contraindications and cautions

Active infection, HIV, malignancy

Monitoring

Monthly FBC, creatinine, urinalysis; TFT

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Monthly blood and urine tests for 4 years after last dose; herpes prophylaxis.

More from the textbook: uses, cautions and other points
Where it is discussed in the book